Physician profile
Bruce N Silverstein
NPI 1649230020
$16,496.45
in general payments reported to CMS, 2019-2025
44 companies · $2,340 in 2025
The $2,340 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,166 · 2020: $1,815 · 2021: $2,261 · 2022: $2,267 · 2023: $2,135 · 2024: $2,511 · 2025: $2,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,986.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,149.39 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,553.13 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,186.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,063.11 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $934.68 | 2019-2023 | Seglentis, Livalo |
| Lilly USA, LLC | $909.49 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $868.94 | 2019-2025 | Vraylar, Qulipta |
| Shield Therapeutics INC | $614.46 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.11 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $493.48 | 2019-2025 | Verquvo, Belsomra, Lagevrio |
| Teva Pharmaceuticals USA, INC. | $454.31 | 2019-2023 | Austedo Xr, Ajovy |
| Exact Sciences Corporation | $392.43 | 2023-2025 | Cologuard Collection Kit |
| Kyowa Kirin, INC. | $280.10 | 2024-2025 | Crysvita |
| Idorsia Pharmaceuticals US INC | $278.02 | 2022-2024 | Quviviq |
| Gilead Sciences, INC. | $264.97 | 2019-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.